Porcilis ColiClos


vaccine to provide passive immunity to the progeny against Escherichia coli and Clostridium perfringens in pigs

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR). Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 26/06/2020

Authorisation details

Product details
Porcilis ColiClos
Agency product number
Active substance
Clostridium perfringens type C / Escherichia coli F4ab / E. coli F4ac / E. coli F5 / E. coli F6 / E. coli LT
International non-proprietary name (INN) or common name
vaccine to provide passive immunity to the progeny against Escherichia coli and Clostridium perfringens in pigs
Anatomical therapeutic chemical veterinary (ATCvet) codes
Publication details
Marketing-authorisation holder
Intervet International BV
Date of issue of marketing authorisation valid throughout the European Union
Contact address
Wim de Körverstraat 35
5831 AN Boxmeer

Product information

19/06/2020 Porcilis ColiClos - EMEA/V/C/002011 - IAIN/0011/G

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group


Therapeutic indication

For the passive immunisation of progeny by active immunisation of sows and gilts to reduce mortality and clinical signs during the first days of life, caused by those Escherichia coli strains which express the adhesins F4ab (K88ab), F4ac (K88ac), F5 (K99) or F6 (987P) and caused by Clostridium perfringens type C.

Assessment history

How useful was this page?

Add your rating